Daskalakis, Nikolaos P.
Rijal, Chuda M.
King, Christopher
Huckins, Laura M.
Ressler, Kerry J.
Article History
First Online: 5 April 2018
Compliance with Ethical Standards
:
: Nikolaos P. Daskalakis, Chuda M. Rijal, Christopher King, and Laura M. Huckins declare no conflict of interest.Kerry J. Ressler is on the Scientific Advisory Boards for Resilience Therapeutics, Sheppard Pratt-Lieber Research Institute, Laureate Institute for Brain Research, The Army STARRS Project, UCSD VA Center of Excellence for Stress and Mental Health—CESAMH, and the Anxiety and Depression Association of America. He provides fee-for-service consultation for Biogen and Resilience Therapeutics. He holds patents for use of D-cycloserine and psychotherapy, targeting PAC1 receptor for extinction, targeting tachykinin 2 for prevention of fear, targeting angiotensin to improve extinction of fear. Dr. Ressler is also founding member of Extinction Pharmaceuticals to develop d-Cycloserine to augment the effectiveness of psychotherapy, for which he has received no equity or income within the last 3 years. He receives or has received research funding from NIMH, HHMI, NARSAD, and the Burroughs Wellcome Foundation.
: This article does not contain any studies with human or animal subjects performed by any of the authors.